INmune Bio Inc. (NASDAQ: INMB) is set to host a webinar on November 7, 2024, to showcase the Early and Mild Alzheimer’s Cognitive Composite (EMACC) as an optimal tool for measuring cognitive change in early Alzheimer’s disease (AD) trials. The webinar aims to highlight the development of EMACC and its advantages in assessing cognitive changes over time in patients with early AD.
EMACC: A Precision Measure for Cognitive Change
The webinar, titled "Why EMACC is the Optimal Tool for Measuring Cognitive Change in Early Alzheimer’s Trials," will feature Dr. Judith Jaeger, President of CognitionMetrics and leader of the team that developed and validated EMACC, along with Dr. Sarah Barnum and CJ Barnum, VP of CNS Drug Development at INmune Bio. The discussion will also cover the regulatory landscape for Alzheimer’s disease drug development and the role of the CDR-SB clinical scale.
Dr. Jaeger stated, "Clinical trials don’t measure disease stage, they measure change in cognition... For early AD trials, the assessments that make up the EMACC objectively and quantitatively capture cognitive change."
CTAD Presentation
The webinar builds on data presented at the 7th annual Clinical Trial in Alzheimer’s Disease (CTAD) conference in Madrid, Spain. The poster, titled "Validation of a precision measure of cognitive change in a phase II clinical trial in early AD: The Early and Mild Alzheimer’s Cognitive Composite (EMACC)," was presented on November 1.
Improving Alzheimer's Clinical Development
CJ Barnum, VP of CNS Drug Development at INmune Bio, noted, "We believe that the EMACC has incredible potential to improve AD clinical development. Improving assessment of cognitive change will lead to smaller, shorter clinical trials, which means less burden on both patients and investors in terms of time and money."
INmune Bio's Phase II Trial
INmune Bio is currently conducting a global, blinded, randomized Phase II trial in patients with Early AD using XPro™. The trial focuses on patients with neuroinflammation. The primary endpoint is the change from baseline cognitive function after 6 months of XPro™ therapy, measured using EMACC and CDR-SB.
About EMACC
EMACC is an empirically validated cognitive measure composed of standardized and widely used neuropsychological tests suited for clinical trials in Early Alzheimer’s Disease (AD). EMACC objectively captures cognitive changes that occur during early AD. It was successfully applied to measure cognitive decline in the Biogen Tango Study of the gosenuremab program (BIIB092). EMACC was also found to be strongly associated with biological markers of inflammation in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) AD study.
